TargetDihydroorotate dehydrogenase (quinone), mitochondrial(malaria parasite P. vivax)
The Board of Regents of The University of Texas System
US Patent
The Board of Regents of The University of Texas System
US Patent
Affinity DataIC50: 12nMAssay Description:The 50% inhibitory concentration (IC50) for the described compounds was determined using the 2,6-dichloroindophenol (DCIP) assay to monitor the DHODH...More data for this Ligand-Target Pair
TargetDihydroorotate dehydrogenase (quinone), mitochondrial(Plasmodium falciparum (isolate 3D7))
The Board of Regents of The University of Texas System
US Patent
The Board of Regents of The University of Texas System
US Patent
Affinity DataIC50: 25nMAssay Description:The 50% inhibitory concentration (IC50) for the described compounds was determined using the 2,6-dichloroindophenol (DCIP) assay to monitor the DHODH...More data for this Ligand-Target Pair
TargetDihydroorotate dehydrogenase (quinone), mitochondrial(Plasmodium falciparum (isolate 3D7))
The Board of Regents of The University of Texas System
US Patent
The Board of Regents of The University of Texas System
US Patent
Affinity DataIC50: 30nMAssay Description:The 50% inhibitory concentration (IC50) for the described compounds was determined using the 2,6-dichloroindophenol (DCIP) assay to monitor the DHODH...More data for this Ligand-Target Pair
TargetDihydroorotate dehydrogenase (quinone), mitochondrial(malaria parasite P. vivax)
The Board of Regents of The University of Texas System
US Patent
The Board of Regents of The University of Texas System
US Patent
Affinity DataIC50: 32nMAssay Description:The 50% inhibitory concentration (IC50) for the described compounds was determined using the 2,6-dichloroindophenol (DCIP) assay to monitor the DHODH...More data for this Ligand-Target Pair
TargetDihydroorotate dehydrogenase (quinone), mitochondrial(Plasmodium falciparum (isolate 3D7))
The Board of Regents of The University of Texas System
US Patent
The Board of Regents of The University of Texas System
US Patent
Affinity DataIC50: 34nMAssay Description:The 50% inhibitory concentration (IC50) for the described compounds was determined using the 2,6-dichloroindophenol (DCIP) assay to monitor the DHODH...More data for this Ligand-Target Pair
TargetDihydroorotate dehydrogenase (quinone), mitochondrial(malaria parasite P. vivax)
The Board of Regents of The University of Texas System
US Patent
The Board of Regents of The University of Texas System
US Patent
Affinity DataIC50: 41nMAssay Description:The 50% inhibitory concentration (IC50) for the described compounds was determined using the 2,6-dichloroindophenol (DCIP) assay to monitor the DHODH...More data for this Ligand-Target Pair
TargetDihydroorotate dehydrogenase (quinone), mitochondrial(malaria parasite P. vivax)
The Board of Regents of The University of Texas System
US Patent
The Board of Regents of The University of Texas System
US Patent
Affinity DataIC50: 41nMAssay Description:The 50% inhibitory concentration (IC50) for the described compounds was determined using the 2,6-dichloroindophenol (DCIP) assay to monitor the DHODH...More data for this Ligand-Target Pair
TargetDihydroorotate dehydrogenase (quinone), mitochondrial(malaria parasite P. vivax)
The Board of Regents of The University of Texas System
US Patent
The Board of Regents of The University of Texas System
US Patent
Affinity DataIC50: 41nMAssay Description:The 50% inhibitory concentration (IC50) for the described compounds was determined using the 2,6-dichloroindophenol (DCIP) assay to monitor the DHODH...More data for this Ligand-Target Pair
TargetDihydroorotate dehydrogenase (quinone), mitochondrial(malaria parasite P. vivax)
The Board of Regents of The University of Texas System
US Patent
The Board of Regents of The University of Texas System
US Patent
Affinity DataIC50: 43nMAssay Description:The 50% inhibitory concentration (IC50) for the described compounds was determined using the 2,6-dichloroindophenol (DCIP) assay to monitor the DHODH...More data for this Ligand-Target Pair
TargetDihydroorotate dehydrogenase (quinone), mitochondrial(malaria parasite P. vivax)
The Board of Regents of The University of Texas System
US Patent
The Board of Regents of The University of Texas System
US Patent
Affinity DataIC50: 43nMAssay Description:The 50% inhibitory concentration (IC50) for the described compounds was determined using the 2,6-dichloroindophenol (DCIP) assay to monitor the DHODH...More data for this Ligand-Target Pair
TargetDihydroorotate dehydrogenase (quinone), mitochondrial(Plasmodium falciparum (isolate 3D7))
The Board of Regents of The University of Texas System
US Patent
The Board of Regents of The University of Texas System
US Patent
Affinity DataIC50: 47nMAssay Description:The 50% inhibitory concentration (IC50) for the described compounds was determined using the 2,6-dichloroindophenol (DCIP) assay to monitor the DHODH...More data for this Ligand-Target Pair
TargetDihydroorotate dehydrogenase (quinone), mitochondrial(Plasmodium falciparum (isolate 3D7))
The Board of Regents of The University of Texas System
US Patent
The Board of Regents of The University of Texas System
US Patent
Affinity DataIC50: 50nMAssay Description:The 50% inhibitory concentration (IC50) for the described compounds was determined using the 2,6-dichloroindophenol (DCIP) assay to monitor the DHODH...More data for this Ligand-Target Pair
TargetDihydroorotate dehydrogenase (quinone), mitochondrial(malaria parasite P. vivax)
The Board of Regents of The University of Texas System
US Patent
The Board of Regents of The University of Texas System
US Patent
Affinity DataIC50: 52nMAssay Description:The 50% inhibitory concentration (IC50) for the described compounds was determined using the 2,6-dichloroindophenol (DCIP) assay to monitor the DHODH...More data for this Ligand-Target Pair
TargetDihydroorotate dehydrogenase (quinone), mitochondrial(Plasmodium falciparum (isolate 3D7))
The Board of Regents of The University of Texas System
US Patent
The Board of Regents of The University of Texas System
US Patent
Affinity DataIC50: 57nMAssay Description:The 50% inhibitory concentration (IC50) for the described compounds was determined using the 2,6-dichloroindophenol (DCIP) assay to monitor the DHODH...More data for this Ligand-Target Pair
TargetDihydroorotate dehydrogenase (quinone), mitochondrial(malaria parasite P. vivax)
The Board of Regents of The University of Texas System
US Patent
The Board of Regents of The University of Texas System
US Patent
Affinity DataIC50: 61nMAssay Description:The 50% inhibitory concentration (IC50) for the described compounds was determined using the 2,6-dichloroindophenol (DCIP) assay to monitor the DHODH...More data for this Ligand-Target Pair
TargetDihydroorotate dehydrogenase (quinone), mitochondrial(malaria parasite P. vivax)
The Board of Regents of The University of Texas System
US Patent
The Board of Regents of The University of Texas System
US Patent
Affinity DataIC50: 72nMAssay Description:The 50% inhibitory concentration (IC50) for the described compounds was determined using the 2,6-dichloroindophenol (DCIP) assay to monitor the DHODH...More data for this Ligand-Target Pair
TargetDihydroorotate dehydrogenase (quinone), mitochondrial(malaria parasite P. vivax)
The Board of Regents of The University of Texas System
US Patent
The Board of Regents of The University of Texas System
US Patent
Affinity DataIC50: 74nMAssay Description:The 50% inhibitory concentration (IC50) for the described compounds was determined using the 2,6-dichloroindophenol (DCIP) assay to monitor the DHODH...More data for this Ligand-Target Pair
TargetDihydroorotate dehydrogenase (quinone), mitochondrial(Plasmodium falciparum (isolate 3D7))
The Board of Regents of The University of Texas System
US Patent
The Board of Regents of The University of Texas System
US Patent
Affinity DataIC50: 76nMAssay Description:The 50% inhibitory concentration (IC50) for the described compounds was determined using the 2,6-dichloroindophenol (DCIP) assay to monitor the DHODH...More data for this Ligand-Target Pair
TargetDihydroorotate dehydrogenase (quinone), mitochondrial(Plasmodium falciparum (isolate 3D7))
The Board of Regents of The University of Texas System
US Patent
The Board of Regents of The University of Texas System
US Patent
Affinity DataIC50: 85nMAssay Description:The 50% inhibitory concentration (IC50) for the described compounds was determined using the 2,6-dichloroindophenol (DCIP) assay to monitor the DHODH...More data for this Ligand-Target Pair
TargetDihydroorotate dehydrogenase (quinone), mitochondrial(Plasmodium falciparum (isolate 3D7))
The Board of Regents of The University of Texas System
US Patent
The Board of Regents of The University of Texas System
US Patent
Affinity DataIC50: 96nMAssay Description:The 50% inhibitory concentration (IC50) for the described compounds was determined using the 2,6-dichloroindophenol (DCIP) assay to monitor the DHODH...More data for this Ligand-Target Pair
TargetDihydroorotate dehydrogenase (quinone), mitochondrial(Plasmodium falciparum (isolate 3D7))
The Board of Regents of The University of Texas System
US Patent
The Board of Regents of The University of Texas System
US Patent
Affinity DataIC50: 98nMAssay Description:The 50% inhibitory concentration (IC50) for the described compounds was determined using the 2,6-dichloroindophenol (DCIP) assay to monitor the DHODH...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform(Homo sapiens (Human))
Petra Pharma
US Patent
Petra Pharma
US Patent
Affinity DataIC50: 110nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6×his tagged p110<...More data for this Ligand-Target Pair
TargetDihydroorotate dehydrogenase (quinone), mitochondrial(Plasmodium falciparum (isolate 3D7))
The Board of Regents of The University of Texas System
US Patent
The Board of Regents of The University of Texas System
US Patent
Affinity DataIC50: 110nMAssay Description:The 50% inhibitory concentration (IC50) for the described compounds was determined using the 2,6-dichloroindophenol (DCIP) assay to monitor the DHODH...More data for this Ligand-Target Pair
TargetDihydroorotate dehydrogenase (quinone), mitochondrial(Plasmodium falciparum (isolate 3D7))
The Board of Regents of The University of Texas System
US Patent
The Board of Regents of The University of Texas System
US Patent
Affinity DataIC50: 140nMAssay Description:The 50% inhibitory concentration (IC50) for the described compounds was determined using the 2,6-dichloroindophenol (DCIP) assay to monitor the DHODH...More data for this Ligand-Target Pair
TargetDihydroorotate dehydrogenase (quinone), mitochondrial(Plasmodium falciparum (isolate 3D7))
The Board of Regents of The University of Texas System
US Patent
The Board of Regents of The University of Texas System
US Patent
Affinity DataIC50: 140nMAssay Description:The 50% inhibitory concentration (IC50) for the described compounds was determined using the 2,6-dichloroindophenol (DCIP) assay to monitor the DHODH...More data for this Ligand-Target Pair
TargetDihydroorotate dehydrogenase (quinone), mitochondrial(malaria parasite P. vivax)
The Board of Regents of The University of Texas System
US Patent
The Board of Regents of The University of Texas System
US Patent
Affinity DataIC50: 170nMAssay Description:The 50% inhibitory concentration (IC50) for the described compounds was determined using the 2,6-dichloroindophenol (DCIP) assay to monitor the DHODH...More data for this Ligand-Target Pair
TargetDihydroorotate dehydrogenase (quinone), mitochondrial(malaria parasite P. vivax)
The Board of Regents of The University of Texas System
US Patent
The Board of Regents of The University of Texas System
US Patent
Affinity DataIC50: 260nMAssay Description:The 50% inhibitory concentration (IC50) for the described compounds was determined using the 2,6-dichloroindophenol (DCIP) assay to monitor the DHODH...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 3-kinase catalytic subunit type 3(Homo sapiens (Human))
Petra Pharma
US Patent
Petra Pharma
US Patent
Affinity DataIC50: 450nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6×his tagged p110<...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform [H1047R](Homo sapiens (Human))
Petra Pharma
US Patent
Petra Pharma
US Patent
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6× his tagged p110...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform [H1047R](Homo sapiens (Human))
Petra Pharma
US Patent
Petra Pharma
US Patent
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6× his tagged p110...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Petra Pharma
US Patent
Petra Pharma
US Patent
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6× his tagged p110...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform [H1047R](Homo sapiens (Human))
Petra Pharma
US Patent
Petra Pharma
US Patent
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6× his tagged p110...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Petra Pharma
US Patent
Petra Pharma
US Patent
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6× his tagged p110...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform [H1047R](Homo sapiens (Human))
Petra Pharma
US Patent
Petra Pharma
US Patent
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6× his tagged p110...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Petra Pharma
US Patent
Petra Pharma
US Patent
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6× his tagged p110...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform [H1047R](Homo sapiens (Human))
Petra Pharma
US Patent
Petra Pharma
US Patent
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6× his tagged p110...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform [H1047R](Homo sapiens (Human))
Petra Pharma
US Patent
Petra Pharma
US Patent
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6× his tagged p110...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Petra Pharma
US Patent
Petra Pharma
US Patent
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6× his tagged p110...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform [H1047R](Homo sapiens (Human))
Petra Pharma
US Patent
Petra Pharma
US Patent
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6× his tagged p110...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Petra Pharma
US Patent
Petra Pharma
US Patent
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6× his tagged p110...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform [H1047R](Homo sapiens (Human))
Petra Pharma
US Patent
Petra Pharma
US Patent
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6× his tagged p110...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform [H1047R](Homo sapiens (Human))
Petra Pharma
US Patent
Petra Pharma
US Patent
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6× his tagged p110...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform [H1047R](Homo sapiens (Human))
Petra Pharma
US Patent
Petra Pharma
US Patent
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6× his tagged p110...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Petra Pharma
US Patent
Petra Pharma
US Patent
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6× his tagged p110...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform [H1047R](Homo sapiens (Human))
Petra Pharma
US Patent
Petra Pharma
US Patent
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6× his tagged p110...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform [H1047R](Homo sapiens (Human))
Petra Pharma
US Patent
Petra Pharma
US Patent
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6× his tagged p110...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform [H1047R](Homo sapiens (Human))
Petra Pharma
US Patent
Petra Pharma
US Patent
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6× his tagged p110...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform [H1047R](Homo sapiens (Human))
Petra Pharma
US Patent
Petra Pharma
US Patent
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6× his tagged p110...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform [H1047R](Homo sapiens (Human))
Petra Pharma
US Patent
Petra Pharma
US Patent
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6× his tagged p110...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform [H1047R](Homo sapiens (Human))
Petra Pharma
US Patent
Petra Pharma
US Patent
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6× his tagged p110...More data for this Ligand-Target Pair